<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01218867</url>
  </required_header>
  <id_info>
    <org_study_id>110013</org_study_id>
    <secondary_id>11-C-0013</secondary_id>
    <nct_id>NCT01218867</nct_id>
  </id_info>
  <brief_title>CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer</brief_title>
  <official_title>Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for
      treating patients metastatic cancer that involves taking white blood cells from the patient,
      growing them in the laboratory in large numbers, genetically modifying these specific cells
      with a type of virus (retrovirus) to attack only the tumor cells, and then giving the cells
      back to the patient. This type of therapy is called gene transfer. In this protocol, we are
      modifying the patient s white blood cells with a retrovirus that has the gene for
      anti-vascular endothelial growth factor receptor (VEGFR2) incorporated in the retrovirus.

      Objectives:

      - To determine a safe number of these cells to infuse and to see the safety and effectiveness
      of cell therapy using anti-VEGFR2 gene modified tumor white blood cells to treat recurrent or
      relapsed cancer.

      Eligibility:

      - Individuals greater than or equal to 18 years of age and less than or equal to 70 years of
      age who have been diagnosed with metastatic cancer that has not responded to or has relapsed
      after standard treatment.

      Design:

        -  Work up stage: Patients will be seen as an outpatient at the National Institutes of
           Health (NIH) clinical Center and undergo a history and physical examination, scans,
           x-rays, lab tests, and other tests as needed

        -  Leukapheresis: If the patients meet all of the requirements for the study they will
           undergo leukapheresis to obtain white blood cells to make the anti-VEGFR2 cells.
           {Leukapheresis is a common procedure which removes only the white blood cells from the
           patient.}

        -  Treatment: Once their cells have grown the patients will be admitted to the hospital for
           the conditioning chemotherapy, the anti-VEGFR2 cells and aldesleukin. They will stay in
           the hospital for about4 weeks for the treatment.

        -  Follow up: Patients will return to the clinic for a physical exam, review of side
           effects, lab tests, and scans about every 1-3 months for the first year, and then every
           6 months to 1 year as long as their tumors are shrinking. Follow up visits will take up
           to 2 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

        -  We have constructed a single retroviral vector that contains a chimeric T cell receptor
           (CAR) that recognizes the Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), which
           can be used to mediate genetic transfer of this CAR with high efficiency (&gt; 50%) without
           the need to perform any selection. Administration of VEGFR2 CAR transduced cells
           inhibited tumor growth in several different models in different mouse strains.

        -  In co-cultures with VEGFR2 expressing cells, anti-VEGFR2 transduced T cells secreted
           significant amounts of interferon (IFN) gamma with high specificity.

      Objectives:

      Primary objectives:

        -  To evaluate the safety of the administration of anti-VEGFR2 CAR engineered cluster of
           differentiation 8 (CD8)+ peripheral blood lymphocytes in patients receiving a non-
           myeloablative conditioning regimen, and aldesleukin.

        -  Determine if the administration of anti-VEGFR2 CAR engineered CD8+ peripheral blood
           lymphocytes and aldesleukin to patients following a nonmyeloablative but lymphoid
           depleting preparative regimen will result in clinical tumor regression in patients with
           metastatic cancer.

      Secondary objective:

      -Determine the in vivo survival of CAR gene-engineered cells.

      Eligibility:

      Patients who are 18 years of age or older must have:

        -  metastatic cancer;

        -  previously received and have been a non-responder to or recurred after standard care for
           metastatic disease;

      Patients may not have:

      -contraindications for high dose aldesleukin administration.

      Design:

        -  Peripheral blood mononuclear cells (PBMC) obtained by leukapheresis (approximately 5
           times 10(9) cells) will be cultured in the presence of anti-CD3 (OKT3) and aldesleukin
           in order to stimulate T-cell growth.

        -  Transduction is initiated by exposure of approximately 10(8) to 5 times 10(8) cells to
           retroviral vector supernatant containing the VEGFR2 genes.

        -  Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen
           consisting of cyclophosphamide and fludarabine followed by intravenous infusion of ex
           vivo CAR gene-transduced CD8+ PBMC plus intravenous (IV) aldesleukin. With approval of
           amendment C, aldesleukin (based on total body weight) will be administered at a dose of
           72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight
           hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up
           to 5 days (maximum 15 doses

        -  Patients will undergo complete evaluation of tumor with physical examination, computed
           tomography (CT) of the chest, abdomen and pelvis and clinical laboratory evaluation four
           to six weeks after treatment. If the patient has stable disease (SD) or tumor shrinkage,
           repeat complete evaluations will be performed every 1-3 months. After the first year,
           patients continuing to respond will continue to be followed with this evaluation every
           3-4 months until off study criteria are met.

        -  The study will be conducted using a Phase I/II optimal design. The protocol will proceed
           in a phase 1 dose escalation design. Initially, the protocol will enroll 1 patient in
           each dose cohort unless that patient experiences a dose limiting toxicity (DLT). Should
           a single patient experience a dose limiting toxicity due to the cell transfer at a
           particular dose level, additional patients would be treated at that dose to confirm that
           no greater than 1/6 patients have a DLT prior to proceeding to the next higher level. If
           a level with 2 or more DLTs in 3-6 patients has been identified, three additional
           patients will be accrued at the next-lowest dose, for a total of 6, in order to further
           characterize the safety of the maximum tolerated dose prior to starting the phase II
           portion. If a dose limiting toxicity occurs in the first cohort, that cohort will be
           expanded to 6 patients. If 2 DLTs are encountered in this cohort, the study will be
           terminated. If IFN-gamma levels increase substantially (as defined in the protocol) in
           the patient in a cohort compared to the prior patient, the cohort would be expanded to
           an n=3 to obtain more data on this phenomenon. If one of these 3 patients experience a
           DLT, the cohort will be expanded to six patients. Following amendment C, patients will
           be enrolled in cohorts 8-11, with the non-myeloablative chemotherapy regimen, cells and
           low dose aldesleukin following a conventional 3+3 design. Once the maximum tolerated
           dose (MTD) has been determined, the study then would proceed to the phase II portion.
           Patients will be entered into two cohorts based on histology: cohort 1 will include
           patients with metastatic melanoma and renal cancer, and cohort 2 will include patients
           with other types of metastatic cancer.

        -  For each of the 2 strata evaluated, the study will be conducted using a phase II optimal
           design where initially 21 evaluable patients will be enrolled. For each of these two
           arms of the trial, if 0 or 1 of the 21 patients experiences a clinical response, then no
           further patients will be enrolled but if 2 or more of the first 21 evaluable patients
           enrolled have a clinical response, then accrual will continue until a total of 41
           evaluable patients have been enrolled in that stratum.

        -  The objective will be to determine if the combination of aldesleukin, lymphocyte
           depleting chemotherapy, and anti-VEGFR2 CAR-gene engineered CD8+ lymphocytes is able to
           be associated with a clinical response rate that can rule out 5% (p0=0.05) in favor of a
           modest 20% partial response (PR) + complete response (CR) rate (p1=0.20).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response to Therapy</measure>
    <time_frame>6 years</time_frame>
    <description>Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is disappearance of all target lesions. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. Progressive disease (PD) is at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment starts or the appearance of one or more new lesions. Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum LD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>33 months and 25 days</time_frame>
    <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In Vivo Survival of Chimeric T Cell Receptor (CAR) Gene-engineered Cells</measure>
    <time_frame>6 years</time_frame>
    <description>Immunological monitoring using both tetramer analysis and staining for the T cell receptor (TCR) will be used to augment polymerase chain reaction (PCR)-based analysis. This will provide data to estimate the in vivo survival of lymphocytes derived from the infused cells.</description>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Metastatic Cancer</condition>
  <condition>Metastatic Melanoma</condition>
  <condition>Renal Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (1x10(6) cells (high dose IL-2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive (1x10(6) cells plus high dose aldesleukin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (3x10(6) cells (high dose IL-2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive (3x10(6) cells plus high dose aldesleukin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 (1x10(7) cells (high dose IL-2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive (1x10(7) cells plus high dose aldesleukin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 (3x10(7) cells (high dose IL-2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive (3x10(7) cells plus high dose aldesleukin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 (1x10(8) cells (high dose IL-2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive (1x10(8) cells plus high dose aldesleukin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6 (3x10(8) cells (high dose IL-2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive (3x10(8) cells plus high dose aldesleukin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7 (1x10(9) cells (high dose IL-2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive (1x10(9) cells plus high dose aldesleukin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8 (1x10(9) cells (low dose IL-2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive (1x10(9) cells plus low dose aldesleukin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9 (3x10(9) cells (low dose IL-2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive (3x10(9) cells plus low dose aldesleukin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort10(1x10(10) cells (low dose IL-2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive (1x10(10) cells plus low dose aldesleukin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort11(3x10(10) cells (low dose IL-2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive (3x10(10) cells plus low dose aldesleukin</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-VEGFR2 CAR CD8 plus PBL</intervention_name>
    <description>Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose (Arms 1-7) or low dose (Arms 8-11) aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)</description>
    <arm_group_label>Cohort 1 (1x10(6) cells (high dose IL-2)</arm_group_label>
    <arm_group_label>Cohort 2 (3x10(6) cells (high dose IL-2)</arm_group_label>
    <arm_group_label>Cohort 3 (1x10(7) cells (high dose IL-2)</arm_group_label>
    <arm_group_label>Cohort 4 (3x10(7) cells (high dose IL-2)</arm_group_label>
    <arm_group_label>Cohort 5 (1x10(8) cells (high dose IL-2)</arm_group_label>
    <arm_group_label>Cohort 6 (3x10(8) cells (high dose IL-2)</arm_group_label>
    <arm_group_label>Cohort 7 (1x10(9) cells (high dose IL-2)</arm_group_label>
    <arm_group_label>Cohort 8 (1x10(9) cells (low dose IL-2)</arm_group_label>
    <arm_group_label>Cohort 9 (3x10(9) cells (low dose IL-2)</arm_group_label>
    <arm_group_label>Cohort10(1x10(10) cells (low dose IL-2)</arm_group_label>
    <arm_group_label>Cohort11(3x10(10) cells (low dose IL-2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose in 5% water (D5W) with mesna 15 mg/kg/day X 2 days over 1 hr</description>
    <arm_group_label>Cohort 1 (1x10(6) cells (high dose IL-2)</arm_group_label>
    <arm_group_label>Cohort 2 (3x10(6) cells (high dose IL-2)</arm_group_label>
    <arm_group_label>Cohort 3 (1x10(7) cells (high dose IL-2)</arm_group_label>
    <arm_group_label>Cohort 4 (3x10(7) cells (high dose IL-2)</arm_group_label>
    <arm_group_label>Cohort 5 (1x10(8) cells (high dose IL-2)</arm_group_label>
    <arm_group_label>Cohort 6 (3x10(8) cells (high dose IL-2)</arm_group_label>
    <arm_group_label>Cohort 7 (1x10(9) cells (high dose IL-2)</arm_group_label>
    <arm_group_label>Cohort 8 (1x10(9) cells (low dose IL-2)</arm_group_label>
    <arm_group_label>Cohort 9 (3x10(9) cells (low dose IL-2)</arm_group_label>
    <arm_group_label>Cohort10(1x10(10) cells (low dose IL-2)</arm_group_label>
    <arm_group_label>Cohort11(3x10(10) cells (low dose IL-2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aldesleukin</intervention_name>
    <description>Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg (Arms 1-7) or 72,000 IU/kg (Arms 8-11) as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)</description>
    <arm_group_label>Cohort 1 (1x10(6) cells (high dose IL-2)</arm_group_label>
    <arm_group_label>Cohort 2 (3x10(6) cells (high dose IL-2)</arm_group_label>
    <arm_group_label>Cohort 3 (1x10(7) cells (high dose IL-2)</arm_group_label>
    <arm_group_label>Cohort 4 (3x10(7) cells (high dose IL-2)</arm_group_label>
    <arm_group_label>Cohort 5 (1x10(8) cells (high dose IL-2)</arm_group_label>
    <arm_group_label>Cohort 6 (3x10(8) cells (high dose IL-2)</arm_group_label>
    <arm_group_label>Cohort 7 (1x10(9) cells (high dose IL-2)</arm_group_label>
    <arm_group_label>Cohort 8 (1x10(9) cells (low dose IL-2)</arm_group_label>
    <arm_group_label>Cohort 9 (3x10(9) cells (low dose IL-2)</arm_group_label>
    <arm_group_label>Cohort10(1x10(10) cells (low dose IL-2)</arm_group_label>
    <arm_group_label>Cohort11(3x10(10) cells (low dose IL-2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days</description>
    <arm_group_label>Cohort 1 (1x10(6) cells (high dose IL-2)</arm_group_label>
    <arm_group_label>Cohort 2 (3x10(6) cells (high dose IL-2)</arm_group_label>
    <arm_group_label>Cohort 3 (1x10(7) cells (high dose IL-2)</arm_group_label>
    <arm_group_label>Cohort 4 (3x10(7) cells (high dose IL-2)</arm_group_label>
    <arm_group_label>Cohort 5 (1x10(8) cells (high dose IL-2)</arm_group_label>
    <arm_group_label>Cohort 6 (3x10(8) cells (high dose IL-2)</arm_group_label>
    <arm_group_label>Cohort 7 (1x10(9) cells (high dose IL-2)</arm_group_label>
    <arm_group_label>Cohort 8 (1x10(9) cells (low dose IL-2)</arm_group_label>
    <arm_group_label>Cohort 9 (3x10(9) cells (low dose IL-2)</arm_group_label>
    <arm_group_label>Cohort10(1x10(10) cells (low dose IL-2)</arm_group_label>
    <arm_group_label>Cohort11(3x10(10) cells (low dose IL-2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

               1. Metastatic cancer with evaluable disease.

               2. Patients must have previously received at least one systemic standard care (or
                  effective salvage chemotherapy regimens) for metastatic disease, if known to be
                  effective for that disease, and have been either non-responders (progressive
                  disease) or have recurred.

               3. Greater than or equal to 18 years of age and less than or equal to 70 years of
                  age.

               4. Willing to sign a durable power of attorney

               5. Able to understand and sign the Informed Consent Document

               6. Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1.

               7. Life expectancy of greater than three months.

               8. Patients of both genders must be willing to practice birth control from the time
                  of enrollment on this study and for up to four months after treatment.

               9. Serology:

                    1. Seronegative for human immunodeficiency virus (HIV) antibody. (The
                       experimental treatment being evaluated in this protocol depends on an intact
                       immune system. Patients who are HIV seropositive can have decreased
                       immune-competence and thus be less responsive to the experimental treatment
                       and more susceptible to its toxicities.)

                    2. Seronegative for hepatitis B antigen, and seronegative for hepatitis C
                       antibody. If hepatitis C antibody test is positive, then patient must be
                       tested for the presence of antigen by reverse transcription-polymerase chain
                       reaction (RT-PCR) and be hepatitis C virus (HCV) ribonucleic acid (RNA)
                       negative.

              10. Hematology:

                    1. Absolute neutrophil count greater than 1000/mm(3) without the support of
                       filgrastim.

                    2. White blood cell (WBC) (&gt; 3000/mm(3)).

                    3. Platelet count greater than 100,000/mm(3).

                    4. Hemoglobin greater than 8.0 g/dl.

              11. Chemistry:

                    1. Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less
                       or equal to 2.5 times the upper limit of normal.

                    2. Serum creatinine less than or equal to 1.6 mg/dl.

                    3. Total bilirubin less than or equal to 1.5 mg/dl, except in patients with
                       Gilberts Syndrome who must have a total bilirubin less than 3.0 mg/dl.

              12. More than four weeks must have elapsed since any prior systemic therapy at the
                  time the patient receives the preparative regimen, and patients toxicities must
                  have recovered to a grade 1 or less (except for toxicities such as alopecia or
                  vitiligo).

              13. More than 4 weeks must have elapsed since an surgical procedure at the time the
                  patient receives the preparative regimen due to the inhibition of wound healing
                  observed with vascular endothelial growth factor receptor (VEGFR) targeting
                  angiogenesis inhibitors.

        EXCLUSION CRITERIA:

          1. Women of child-bearing potential who are pregnant or breastfeeding because of the
             potentially dangerous effects of the treatment on the fetus or infant.

          2. Patients with known brain metastases.

          3. Patients receiving full dose anticoagulative therapy.

          4. Active systemic infections, coagulation disorders or other major medical illnesses of
             the cardiovascular, respiratory or immune system, myocardial infarction, cardiac
             arrhythmias, obstructive or restrictive pulmonary disease.

          5. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency
             Disease).

          6. Concurrent opportunistic infections (The experimental treatment being evaluated in
             this protocol depends on an intact immune system. Patients who have decreased immune
             competence may be less responsive to the experimental treatment and more susceptible
             to its toxicities).

          7. Patients with diabetic retinopathy.

          8. Concurrent Systemic steroid therapy.

          9. History of severe immediate hypersensitivity reaction to any of the agents used in
             this study.

         10. History of coronary revascularization or ischemic symptoms.

         11. In patients

        Documented forced expiratory volume 1 (FEV1) less than or equal to 45% predicted tested in
        patients with:

          1. History of ischemic heart disease, chest pain, or clinically significant atrial and/or
             ventricular arrhythmias including but not limited to: atrial fibrillation, ventricular
             tachycardia, second or third degree heart block.

          2. Age greater than or equal to 60 years old.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A Rosenberg, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2011-C-0013.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature. 2001 May 17;411(6835):380-4. Review.</citation>
    <PMID>11357146</PMID>
  </reference>
  <reference>
    <citation>Berendt MJ, North RJ. T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med. 1980 Jan 1;151(1):69-80.</citation>
    <PMID>6444236</PMID>
  </reference>
  <reference>
    <citation>Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006 May;6(5):383-93. Review.</citation>
    <PMID>16622476</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2010</study_first_submitted>
  <study_first_submitted_qc>October 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2010</study_first_posted>
  <results_first_submitted>April 15, 2016</results_first_submitted>
  <results_first_submitted_qc>June 9, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 22, 2016</results_first_posted>
  <last_update_submitted>November 8, 2016</last_update_submitted>
  <last_update_submitted_qc>November 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Steven Rosenberg, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Clinical Response</keyword>
  <keyword>Metastatic Cancer</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Adoptive Cell Therapy</keyword>
  <keyword>Metastatic Melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Twenty-four participants were enrolled but one participant was not treated due to a new cancer diagnosis which made the participant ineligible for this protocol.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1 - 1 x 10(6) Cells (High Dose IL-2)</title>
          <description>Anti-vascular endothelial growth factor receptor 2 (VEGFR2) chimeric T cell receptor (CAR) cluster of differentiation 8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2 - 3 x 10(6) Cells (High Dose IL-2)</title>
          <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3 - 1 x 10(7) Cells (High Dose IL-2)</title>
          <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
        <group group_id="P4">
          <title>Cohort 4 - 3 x 10(7) Cells (High Dose IL-2)</title>
          <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
        <group group_id="P5">
          <title>Cohort 5 - 1 x 10(8) Cells (High Dose IL-2)</title>
          <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
        <group group_id="P6">
          <title>Cohort 6 - 3 x 10(8) Cells (High Dose IL-2)</title>
          <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
        <group group_id="P7">
          <title>Cohort 7 - 1 x 10(9) Cells (High Dose IL-2)</title>
          <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
        <group group_id="P8">
          <title>Cohort 8 - 1 x 10(9) Cells (Low Dose IL-2)</title>
          <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
        <group group_id="P9">
          <title>Cohort 9 - 3 x 10(9) Cells (Low Dose IL-2)</title>
          <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
        <group group_id="P10">
          <title>Cohort 10 - 1 x 10(10) Cells (Low Dose IL-2)</title>
          <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
        <group group_id="P11">
          <title>Cohort 11 - 3 x 10(10) Cells (Low Dose IL-2)</title>
          <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="4"/>
                <participants group_id="P11" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="4"/>
                <participants group_id="P11" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death during treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1 - 1 x 10(6) Cells (High Dose IL-2)</title>
          <description>Anti-vascular endothelial growth factor receptor 2 (VEGFR2) Chimeric T cell receptor (CAR) CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2 - 3 x 10(6) Cells (High Dose IL-2)</title>
          <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3 - 1 x 10(7) Cells (High Dose IL-2)</title>
          <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
        <group group_id="B4">
          <title>Cohort 4 - 3 x 10(7) Cells (High Dose IL-2)</title>
          <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
        <group group_id="B5">
          <title>Cohort 5 - 1 x 10(8) Cells (High Dose IL-2)</title>
          <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
        <group group_id="B6">
          <title>Cohort 6 - 3 x 10(8) Cells (High Dose IL-2)</title>
          <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
        <group group_id="B7">
          <title>Cohort 7 - 1 x 10(9) Cells (High Dose IL-2)</title>
          <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
        <group group_id="B8">
          <title>Cohort 8 - 1 x 10(9) Cells (Low Dose IL-2)</title>
          <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
        <group group_id="B9">
          <title>Cohort 9 - 3 x 10(9) Cells (Low Dose IL-2)</title>
          <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
        <group group_id="B10">
          <title>Cohort 10 - 1 x 10(10) Cells (Low Dose IL-2)</title>
          <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
        <group group_id="B11">
          <title>Cohort 11 - 3 x 10(10) Cells (Low Dose IL-2)</title>
          <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
        <group group_id="B12">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="1"/>
            <count group_id="B5" value="1"/>
            <count group_id="B6" value="1"/>
            <count group_id="B7" value="4"/>
            <count group_id="B8" value="3"/>
            <count group_id="B9" value="3"/>
            <count group_id="B10" value="4"/>
            <count group_id="B11" value="2"/>
            <count group_id="B12" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.0" spread="0"/>
                    <measurement group_id="B2" value="51.0" spread="0"/>
                    <measurement group_id="B3" value="52.7" spread="12.1"/>
                    <measurement group_id="B4" value="65.0" spread="0"/>
                    <measurement group_id="B5" value="55.0" spread="0"/>
                    <measurement group_id="B6" value="35.0" spread="0"/>
                    <measurement group_id="B7" value="45.5" spread="11.3"/>
                    <measurement group_id="B8" value="37.0" spread="18.0"/>
                    <measurement group_id="B9" value="54.7" spread="11.9"/>
                    <measurement group_id="B10" value="46.3" spread="5.6"/>
                    <measurement group_id="B11" value="41.5" spread="10.6"/>
                    <measurement group_id="B12" value="47.9" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response to Therapy</title>
        <description>Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is disappearance of all target lesions. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. Progressive disease (PD) is at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment starts or the appearance of one or more new lesions. Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum LD.</description>
        <time_frame>6 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - 1x10(6) Cells (High Dose IL-2)</title>
            <description>Anti-vascular endothelial growth factor receptor 2 (VEGFR2) Chimeric T cell receptor (CAR) CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 - 3x10(6) Cells (High Dose IL-2)</title>
            <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 - 1x10(7) Cells (High Dose IL-2)</title>
            <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 - 3x10(7) Cells (High Dose IL-2)</title>
            <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5 - 1x10(8) Cells (High Dose IL-2)</title>
            <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6 - 3x10(8) Cells (High Dose IL-2)</title>
            <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7 - 1x10(9) Cells (High Dose IL-2)</title>
            <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
          <group group_id="O8">
            <title>Cohort 8 - 1x10(9) Cells (Low Dose IL-2)</title>
            <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
          <group group_id="O9">
            <title>Cohort 9 - 3x10(9) Cells (Low Dose IL-2)</title>
            <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
          <group group_id="O10">
            <title>Cohort 10 - 1x10(10) Cells (Low Dose IL-2)</title>
            <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
          <group group_id="O11">
            <title>Cohort 11 - 3x10(10) Cells (Low Dose IL-2)</title>
            <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Response to Therapy</title>
          <description>Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is disappearance of all target lesions. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. Progressive disease (PD) is at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment starts or the appearance of one or more new lesions. Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum LD.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease (PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.</description>
        <time_frame>33 months and 25 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - 1 x 10(6) Cells (High Dose IL-2)</title>
            <description>Anti-vascular endothelial growth factor receptor 2(VEGFR2) chimeric T cell receptor (CAR) CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 - 3 x 10(6) Cells (High Dose IL-2)</title>
            <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 - 1 x 10(7) Cells (High Dose IL-2)</title>
            <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 - 3 x 10(7) Cells (High Dose IL-2)</title>
            <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5 - 1 x 10(8) Cells (High Dose IL-2)</title>
            <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6 - 3 x 10(8) Cells (High Dose IL-2)</title>
            <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7 - 1 x 10(9) Cells (High Dose IL-2)</title>
            <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
          <group group_id="O8">
            <title>Cohort 8 - 1 x 10(9) Cells (Low Dose IL-2)</title>
            <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
          <group group_id="O9">
            <title>Cohort 9 - 3 x 10(9) Cells (Low Dose IL-2)</title>
            <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
          <group group_id="O10">
            <title>Cohort 10 - 1 x 10(10) Cells (Low Dose IL-2)</title>
            <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
          <group group_id="O11">
            <title>Cohort 11 - 3 x 10(10) Cells (Low Dose IL-2)</title>
            <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In Vivo Survival of Chimeric T Cell Receptor (CAR) Gene-engineered Cells</title>
        <description>Immunological monitoring using both tetramer analysis and staining for the T cell receptor (TCR) will be used to augment polymerase chain reaction (PCR)-based analysis. This will provide data to estimate the in vivo survival of lymphocytes derived from the infused cells.</description>
        <time_frame>6 years</time_frame>
        <population>This outcome measure was not done due to the lack of a minimum number (e.g. 4) of required durable responses in the participants. A durable response is defined as a complete response, partial response, or stable disease in at least 4 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - 1 x 10(6) Cells (High Dose IL-2)</title>
            <description>Anti-vascular endothelial growth factor receptor 2(VEGFR2) chimeric T cell receptor (CAR) CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 - 3 x 10(6) Cells (High Dose IL-2)</title>
            <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 - 1 x 10(7) Cells (High Dose IL-2)</title>
            <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 - 3 x 10(7) Cells (High Dose IL-2)</title>
            <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5 - 1 x 10(8) Cells (High Dose IL-2)</title>
            <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6 - 3 x 10(8) Cells (High Dose IL-2)</title>
            <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7 - 1 x 10(9) Cells (High Dose IL-2)</title>
            <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
          <group group_id="O8">
            <title>Cohort 8 - 1 x 10(9) Cells (Low Dose IL-2)</title>
            <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
          <group group_id="O9">
            <title>Cohort 9 - 3 x 10(9) Cells (Low Dose IL-2)</title>
            <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
          <group group_id="O10">
            <title>Cohort 10 - 1 x 10(10) Cells (Low Dose IL-2)</title>
            <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
          <group group_id="O11">
            <title>Cohort 11 - 3 x 10(10) Cells (Low Dose IL-2)</title>
            <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>In Vivo Survival of Chimeric T Cell Receptor (CAR) Gene-engineered Cells</title>
          <description>Immunological monitoring using both tetramer analysis and staining for the T cell receptor (TCR) will be used to augment polymerase chain reaction (PCR)-based analysis. This will provide data to estimate the in vivo survival of lymphocytes derived from the infused cells.</description>
          <population>This outcome measure was not done due to the lack of a minimum number (e.g. 4) of required durable responses in the participants. A durable response is defined as a complete response, partial response, or stable disease in at least 4 participants.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1 (1x10(6) Cells (High Dose IL-2)</title>
          <description>Anti-vascular endothelial growth factor receptor 2 (VEGFR2) chimeric T cell receptor (CAR) CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2 (3x10(6) Cells (High Dose IL-2)</title>
          <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
        <group group_id="E3">
          <title>Cohort 3 (1x10(7) Cells (High Dose IL-2)</title>
          <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
        <group group_id="E4">
          <title>Cohort 4 (3x10(7) Cells (High Dose IL-2)</title>
          <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
        <group group_id="E5">
          <title>Cohort 5 (1x10(8) Cells (High Dose IL-2)</title>
          <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
        <group group_id="E6">
          <title>Cohort 6 (1x10(8) Cells (High Dose IL-2)</title>
          <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
        <group group_id="E7">
          <title>Cohort 7 (1x10(9) Cells (High Dose IL-2)</title>
          <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
        <group group_id="E8">
          <title>Cohort 8 (1x10(9) Cells (Low Dose IL-2)</title>
          <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
        <group group_id="E9">
          <title>Cohort 9 (3x10(9) Cells (Low Dose IL-2)</title>
          <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
        <group group_id="E10">
          <title>Cohort 10 (1x10(10) Cells (Low Dose IL-2)</title>
          <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
        <group group_id="E11">
          <title>Cohort 11 (3x10(10) Cells (Low Dose IL-2)</title>
          <description>Anti-VEGFR2 CAR CD8 plus PBL: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and low dose aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
Aldesleukin: Aldesleukin (based on total body weight) will be administered at a dose of 72,000 IU/kg as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>AST, SGOT (serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Leukocytes (Total WBC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>PTT (Partial Thromboplstin Time)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing: patients with/without baseline audiogram and enrolled in a monitoring program</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular/Visual-Other (vision changes)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Syndromes - Other (hemaphogocytic syndrome)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver dysfunction/failure (clinical)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>(fever of unknown origin without clinically or microbiologically documented infection) (ANC &lt;1.0 x 10e9/L, fever &gt;=38.5 degrees C)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Phosphate, serum-low (hypophosphatemia)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Calcium, serum-low (hypocalcemia)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Potassium, serum-low (hypokalemia)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>AST, SGOT (serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Uric acid, serum-high (hyperuricemia)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Psychosis (hallucinations/delusions)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Somnolence/depressed level of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Syncope (fainting)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, GU</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Renal/Genitourinary - Other (low urine output)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Acute vascular leak syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Steven Rosenberg</name_or_title>
      <organization>National Cancer Institute</organization>
      <phone>301- 496-4164</phone>
      <email>sar@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

